ATRS - Antares Pharma Q4 2021 Earnings Preview
Antares Pharma (NASDAQ:ATRS) is scheduled to announce Q4 earnings results on Thursday, Mar. 3, before market open. The consensus EPS estimate is $0.01 and the consensus revenue estimate is $47.19M (+7% Y/Y). Over the last 2 years, ATRS has beaten EPS estimates 75% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 0 upward revisions and 2 downward. SA contributor Andy Jones recently wrote "A Look At Recent Moves By Antares Pharma", rating the stock Buy.
For further details see:
Antares Pharma Q4 2021 Earnings Preview